January/February 2000

Vol 7, No 1 CME Pretest

This Journal provides 4 hours of Category 1 Continuing Medical Education

Complimentary CME Credits

Physicians can earn 4 credit hours of Category 1 for the Physician's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions in the posttest at the end of this issue. Complete instructions are given on the posttest pages. Successfully answering 30 or more questions will earn 4 credit hours. CME is presented by an unrestricted educational grant from Bristol-Myers Squibb Oncology Division.

Educational Objectives

After reading this issue of Cancer Control, clinicians will be expected to:

• understand the advances in prevention and early detection of lung cancer,
• appreciate the progress in management of both early and later stages of lung cancer, and
• discuss the biology and management of cutaneous Merkel cell lines.

Release Date: January 1, 2000
Expiration Date: January 1, 2001

Pretest

1. Carcinoma in situ (CIS) of the lung is usually which histology?

a. large cell

b. small cell

c. adenocarcinoma

d. squamous cell

2. A phase II trial (the Bimodality Lung Oncology Trial) of induction chemotherapy (paclitaxel plus carboplatin) in patients with stages IB, IIA, and IIB non-small cell lung cancer reported what incidence of major responses?

a. 88%

b. 54%

c. 35%

d. 27%

3. Which region of the skin is most often affected by neuroendocrine carcinoma?

a. head and neck

b. back

c. chest wall

d. extremities